{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:00:09Z","timestamp":1790290809301,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40266-022-00924-3","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T21:02:57Z","timestamp":1646254977000},"page":"235-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Hexanic Extract of Serenoa repens (Permixon\u00ae): A Review in Symptomatic Benign Prostatic Hyperplasia"],"prefix":"10.1007","volume":"39","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"924_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00658","author":"ZJ Yu","year":"2020","unstructured":"Yu ZJ, Yan HL, Xu FH, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00658.","journal-title":"Front Pharmacol"},{"issue":"11","key":"924_CR2","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00345-020-03106-1","volume":"38","author":"C De Nunzio","year":"2020","unstructured":"De Nunzio C, Salonia A, Gacci M, et al. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol. 2020;38(11):2771\u20139.","journal-title":"World J Urol"},{"issue":"2","key":"924_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pop.2019.02.003","volume":"46","author":"RC Langan","year":"2019","unstructured":"Langan RC. Benign prostatic hyperplasia. Prim Care. 2019;46(2):223\u201332.","journal-title":"Prim Care"},{"key":"924_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/uro1030015","volume":"1","author":"SB Strum","year":"2021","unstructured":"Strum SB. Serenoa repens (Saw palmetto) for lower urinary tract symptoms (LUTS): the evidence for efficacy and safety of lipidosterolic extracts. Part I. Uro. 2021;1:118\u201338.","journal-title":"Uro"},{"issue":"2208","key":"924_CR5","first-page":"1","volume":"24","author":"G Marti","year":"2019","unstructured":"Marti G, Joulia P, Amiel A, et al. Comparison of the phytochemical composition of Serenoa repens extracts by a multiplexed metabolomic approach. Molecules. 2019;24(2208):1\u201314.","journal-title":"Molecules"},{"key":"924_CR6","unstructured":"European Medicines Agency. European Union herbal monograph on Serenoa repens (W. Bartram) small, fructus. 2014. https:\/\/www.ema.europa.eu\/en\/documents\/herbal-monograph\/draft-european-union-herbal-monograph-serenoa-repens-w-bartram-small-fructus_en.pdf. Accessed 8 Feb 2022."},{"key":"924_CR7","unstructured":"European Medicines Agency. Assessment report on Serenoa repens (W. Bartram) small, fructus. Final. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/herbal-report\/final-assessment-report-serenoa-repens-w-bartram-small-fructus_en.pdf. Accessed 8 Feb 2022."},{"key":"924_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-14-63","author":"C De Monte","year":"2014","unstructured":"De Monte C, Carradori S, Granese A, et al. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol. 2014. https:\/\/doi.org\/10.1186\/1471-2490-14-63.","journal-title":"BMC Urol"},{"issue":"4","key":"924_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E","volume":"29","author":"JC Carraro","year":"1996","unstructured":"Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon\u00ae) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29(4):231\u201340.","journal-title":"Prostate"},{"issue":"5","key":"924_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2165\/00002512-199609050-00008","volume":"9","author":"GL Plosker","year":"1996","unstructured":"Plosker GL, Brogden RN. Serenoa repens (Permixon\u00ae). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9(5):379\u201395.","journal-title":"Drugs Aging"},{"issue":"3","key":"924_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00345-018-2409-1","volume":"37","author":"S Gravas","year":"2019","unstructured":"Gravas S, Samarinas M, Zacharouli K, et al. The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World J Urol. 2019;37(3):539\u201344.","journal-title":"World J Urol"},{"issue":"16","key":"924_CR12","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/pros.23059","volume":"75","author":"A Latil","year":"2015","unstructured":"Latil A, P\u00e9trissans MT, Rouquet J, et al. Effects of hexanic extract of Serenoa repens (Permixon\u00ae 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75(16):1857\u201367.","journal-title":"Prostate"},{"key":"924_CR13","first-page":"21","volume":"15","author":"MB De di Valserra","year":"1994","unstructured":"De di Valserra MB, Tripodi AS, Contos S, et al. Serenoa repens capsules: a bioequivalence study. Acta Toxicol Ther. 1994;15:21\u201339.","journal-title":"Acta Toxicol Ther."},{"key":"924_CR14","unstructured":"Raynaud JP, Girault J, Vinclair P, et al. Absorption of 2 of the main components of the lipido-sterolic extract of Serenoa repens (Permixon\u00ae) in human volunteers [abstract]. In: 5th International consultation on BPH. 2000."},{"issue":"1","key":"924_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF03189787","volume":"22","author":"G Chevalier","year":"1997","unstructured":"Chevalier G, Benard P, Cousse H, et al. Distribution study of radioactivity in rats after oral administration of the lipido\/sterolic extract of Serenoa repens (Permixon\u00ae) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-\u03b2-sitosterol. Eur J Drug Metab Pharmacokinet. 1997;22(1):73\u201383.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"924_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0302-2838(02)00066-0","volume":"41","author":"F Debruyne","year":"2002","unstructured":"Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an \u03b1-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol. 2002;41(5):497\u2013506.","journal-title":"Eur Urol"},{"issue":"3","key":"924_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.pcan.4500477","volume":"3","author":"SH Al-Shukri","year":"2000","unstructured":"Al-Shukri SH, Deschaseaux P, Kuzmin IV, et al. Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon\u00ae) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2000;3(3):195\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"924_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0302-2838(03)00368-3","volume":"44","author":"RV Navarrete","year":"2003","unstructured":"Navarrete RV, Cardoso JVG, Barat A, et al. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44(5):549\u201355.","journal-title":"Eur Urol"},{"issue":"6","key":"924_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02853175","volume":"19","author":"YA Pytel","year":"2002","unstructured":"Pytel YA, Vinarov A, Lopatkin N, et al. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther. 2002;19(6):297\u2013306.","journal-title":"Adv Ther"},{"issue":"6","key":"924_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.eururo.2004.01.015","volume":"45","author":"F Debruyne","year":"2004","unstructured":"Debruyne F, Boyle P, Da Silva FD, et al. Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol. 2004;45(6):773\u20139.","journal-title":"Eur Urol"},{"issue":"5","key":"924_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11255-015-1206-7","volume":"48","author":"A Alcaraz","year":"2016","unstructured":"Alcaraz A, Carballido-Rodriguez J, Unda-Urzaiz M, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment\u2014the QUALIPROST study. Int Urol Nephrol. 2016;48(5):645\u201356.","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"924_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.purol.2020.07.001","volume":"30","author":"A de la Taille","year":"2020","unstructured":"de la Taille A, Bardin L, Castagn\u00e9 C, et al. Alpha-bloquants ou phytoth\u00e9rapie en traitement de premi\u00e8re intention des SBAU\/HBP en m\u00e9decine g\u00e9n\u00e9rale: l\u2019\u00e9tude non interventionnelle PERSAT [Alpha-blockers or phytotherapy as first-line treatment of LUTS\/BPH in general medicine: the PERSAT non-interventional study]. Prog Urol. 2020;30(10):522\u201331.","journal-title":"Prog Urol"},{"issue":"1","key":"924_CR23","doi-asserted-by":"publisher","first-page":"19401","DOI":"10.1038\/s41598-021-98586-5","volume":"11","author":"A Alcaraz","year":"2021","unstructured":"Alcaraz A, Rodriguez-Antolin A, Carballido-Rodriguez J, et al. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients. Sci Rep. 2021;11(1):19401.","journal-title":"Sci Rep"},{"issue":"13","key":"924_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.purol.2021.08.044","volume":"31","author":"A de la Taille","year":"2021","unstructured":"de la Taille A, du Rieu QC, Bardin L. Alpha-bloquants ou Permixon\u00ae pendant 6 mois\u202f: r\u00e9sultats d\u2019une sous-population de l\u2019\u00e9tude PERSAT [Alpha-blockers or Permixon\u00ae for 6 months: results from a subpopulation of the study PERSAT] [abstract no. CO-01]. Prog Urol. 2021;31(13):773.","journal-title":"Prog Urol"},{"issue":"2","key":"924_CR25","first-page":"94","volume":"84","author":"R Giulianelli","year":"2012","unstructured":"Giulianelli R, Pecoraro S, Sepe G, et al. Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation. Arch Ital Urol Androl. 2012;84(2):94\u20138.","journal-title":"Arch Ital Urol Androl"},{"issue":"10","key":"924_CR26","first-page":"1403","volume":"77","author":"JL Edwards","year":"2008","unstructured":"Edwards JL. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician. 2008;77(10):1403\u201310.","journal-title":"Am Fam Physician"},{"key":"924_CR27","unstructured":"Gravas S, Cornu J, Gacci M, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2021. https:\/\/uroweb.org\/guideline\/treatment-of-non-neurogenic-male-luts\/. Accessed 8 Feb 2022."},{"issue":"4","key":"924_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/1756287211418725","volume":"3","author":"P Geavlete","year":"2011","unstructured":"Geavlete P, Multescu R, Geavlete B. Serenoa repens extract in the treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011;3(4):193\u20138.","journal-title":"Ther Adv Urol"},{"issue":"6","key":"924_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1464-410X.2003.04735.x","volume":"93","author":"P Boyle","year":"2004","unstructured":"Boyle P, Robertson C, Lowe F, et al. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. 2004;93(6):751\u20136.","journal-title":"BJU Int"},{"issue":"5","key":"924_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.euf.2016.04.002","volume":"2","author":"G Novara","year":"2016","unstructured":"Novara G, Giannarini G, Alcaraz A, et al. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus. 2016;2(5):553\u201361.","journal-title":"Eur Urol Focus"},{"issue":"6","key":"924_CR31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/bju.14362","volume":"122","author":"R Vela-Navarrete","year":"2018","unstructured":"Vela-Navarrete R, Alcaraz A, Rodr\u00edguez-Antol\u00edn A, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon\u00ae) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS\/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122(6):1049\u201365.","journal-title":"BJU Int"},{"issue":"2","key":"924_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.eururo.2005.03.029","volume":"48","author":"AR Zlotta","year":"2005","unstructured":"Zlotta AR, Teillac P, Raynaud JP, et al. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon\u00ae), tamsulosin or finasteride. Eur Urol. 2005;48(2):269\u201376.","journal-title":"Eur Urol"},{"issue":"6","key":"924_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s12325-012-0024-x","volume":"29","author":"R Perry","year":"2012","unstructured":"Perry R, Milligan G, Anderson P, et al. Real-world use of Permixon\u00ae in benign prostatic hyperplasia\u2013determining appropriate monotherapy and combination treatment. Adv Ther. 2012;29(6):538\u201350.","journal-title":"Adv Ther"},{"key":"924_CR34","unstructured":"Ragab A, Ragab-Thomas JMF, Delhon A, et al. Effects of Permixon\u00ae (Sereprostat\u00ae in Spain) on phospholipase A2 activity and on arachidonic acid metabolism in cultured prostatic cells. Acta Medica. 1987:293-6."},{"issue":"3","key":"924_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0952-3278(97)90548-2","volume":"57","author":"M Paubert-Braquet","year":"1997","unstructured":"Paubert-Braquet M, Mencia Huerta JM, Cousse H, et al. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon\u00ae) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57(3):299\u2013304.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"924_CR36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.eursup.2013.08.003","volume":"12","author":"A de la Taille","year":"2013","unstructured":"de la Taille A. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116\u201322.","journal-title":"Eur Urol Suppl"},{"issue":"2","key":"924_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1569-9056(10)60619-7","volume":"9","author":"A Latil","year":"2010","unstructured":"Latil A, Lantoine-Adam F, Aguilar L, et al. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results [abstract no. 630]. Eur Urol Suppl. 2010;9(2):209.","journal-title":"Eur Urol Suppl"},{"issue":"6 Pt B","key":"924_CR38","doi-asserted-by":"publisher","first-page":"E301","DOI":"10.1111\/j.1464-410X.2012.11144.x","volume":"110","author":"A Latil","year":"2012","unstructured":"Latil A, Libon C, Templier M, et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1\/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110(6 Pt B):E301\u20137.","journal-title":"BJU Int"},{"issue":"4","key":"924_CR39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S1569-9056(09)60355-9","volume":"8","author":"A Latil","year":"2009","unstructured":"Latil A, Verscheure Y, Tisne-Versailles J, et al. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammatory status [abstract no. 352]. Eur Urol Suppl. 2009;8(4):208.","journal-title":"Eur Urol Suppl"},{"issue":"7","key":"924_CR40","doi-asserted-by":"publisher","first-page":"14301","DOI":"10.3390\/ijms140714301","volume":"14","author":"N Sirab","year":"2013","unstructured":"Sirab N, Robert G, Fasolo V, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14(7):14301\u201320.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"924_CR41","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/pros.22953","volume":"75","author":"S Bernichtein","year":"2015","unstructured":"Bernichtein S, Pigat N, Camparo P, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon\u00ae) in a mouse model of prostate hyperplasia. Prostate. 2015;75(7):706\u201322.","journal-title":"Prostate"},{"issue":"11","key":"924_CR42","first-page":"1","volume":"10","author":"I Silvestri","year":"2013","unstructured":"Silvestri I, Cattarino S, Agliano A, et al. Effect of Serenoa repens (Permixon\u00ae) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma. J Inflamm. 2013;10(11):1\u20139.","journal-title":"J Inflamm"},{"issue":"3","key":"924_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G","volume":"45","author":"F Vacherot","year":"2000","unstructured":"Vacherot F, Azzouz M, Gil-Diez-De-Medina S, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon\u00ae) in benign prostatic hyperplasia. Prostate. 2000;45(3):259\u201366.","journal-title":"Prostate"},{"issue":"2","key":"924_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/01.ju.0000150533.94952.25","volume":"173","author":"R Vela-Navarrete","year":"2005","unstructured":"Vela-Navarrete R, Escribano-Burgos M, Farr\u00e9 AL, et al. Serenoa repens treatment modifies Bax\/Bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol. 2005;173(2):507\u201310.","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"924_CR45","first-page":"876","volume":"164","author":"CW Bayne","year":"2000","unstructured":"Bayne CW, Ross M, Donnelly F, et al. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon\u00ae) on the prostate. J Urol. 2000;164(3 Pt 1):876\u201381.","journal-title":"J Urol"},{"issue":"2","key":"924_CR46","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/ijc.20701","volume":"114","author":"FK Habib","year":"2005","unstructured":"Habib FK, Ross M, Ho CK, et al. Serenoa repens (Permixon\u00ae) inhibits the 5\u03b1-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer. 2005;114(2):190\u20134.","journal-title":"Int J Cancer"},{"issue":"2","key":"924_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/(SICI)1097-0045(19981001)37:2<77::AID-PROS3>3.0.CO;2-I","volume":"37","author":"F Di Silverio","year":"1998","unstructured":"Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon\u00ae) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998;37(2):77\u201383.","journal-title":"Prostate"}],"updated-by":[{"DOI":"10.1007\/s40266-022-00936-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000}}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00924-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-022-00924-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00924-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T02:30:11Z","timestamp":1655087411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-022-00924-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1007\/s40266-022-00924-3","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"7 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40266-022-00936-z","URL":"https:\/\/doi.org\/10.1007\/s40266-022-00936-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}